Stocks Health care CVKD
NASDAQ · Health careCadrenal Therapeutics, Inc. (CVKD)
It posted a net loss of $11.5M. In fiscal 2025 capital spending exceeded operating cash flow by $12.6M. At June 30, 2026 it held $2.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Cadrenal Therapeutics, Inc.
- Net worth
- Cadrenal Therapeutics, Inc. has a market value (market cap) of $5.2M at the latest share price, and shareholders' equity of $4.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $12.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cadrenal Therapeutics, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
- Dividend
- Cadrenal Therapeutics, Inc. declared dividends of $16.50 per share in fiscal 2025, a yield of 1,137.93% at the current price.
What Cadrenal Therapeutics, Inc. does
Cadrenal Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CVKD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$13.2M | -$6.64 | -$12.6M |
| 2024 | n/a | -$10.7M | -$8.73 | -$7.4M |
| 2023 | n/a | -$8.4M | -$9.29 | -$3.5M |
| 2022 | n/a | -$6.7M | -$12.74 | -$1.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Dividends
Cadrenal Therapeutics, Inc. declared $16.50 per share in fiscal 2025. At the current price that is a yield of 1,137.93%.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $16.50 | n/a | n/a |
| 2024 | $16.50 | n/a | n/a |
Latest SEC filings
What Cadrenal Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026Executive or director change8-KCadrenal Therapeutics stockholders approved all proposals at the 2026 annual meeting, including an equity plan expansion and warrant share issuance.
- September 3, 2026
- August 31, 2026
- August 13, 2026
- August 13, 2026
- August 3, 2026Additional proxy material DEFA14A
- August 3, 2026
- August 3, 2026Proxy statement DEF 14A
- July 23, 2026Preliminary proxy statement PRE 14A
- July 21, 2026
Insider trades
What the people running Cadrenal Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 29, 2026 | Pham Quang XChairman and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 7,400 | $22.4K |
| June 26, 2026 | Pham Quang XChairman, CEO and Interim CFO, Director, 10% owner | Soldpre-planned (10b5-1) | 9,029 | $27.5K |
| June 25, 2026 | Pham Quang XChairman, CEO and Interim CFO, Director, 10% owner | Soldpre-planned (10b5-1) | 2,127 | $6.4K |
| June 23, 2026 | Pham Quang XChairman, CEO and Interim CFO, Director, 10% owner | Soldpre-planned (10b5-1) | 2,277 | $7.3K |
| June 22, 2026 | Pham Quang XChairman, CEO and Interim CFO, Director, 10% owner | Soldpre-planned (10b5-1) | 9,167 | $32.5K |
| June 17, 2026 | Pham Quang XChairman, CEO and Interim CFO, Director, 10% owner | Soldpre-planned (10b5-1) | 513 | $1.6K |
| June 16, 2026 | Pham Quang XChairman, CEO and Interim CFO, Director, 10% owner | Soldpre-planned (10b5-1) | 3,613 | $11.5K |
| June 15, 2026 | Pham Quang XChairman, CEO and Interim CFO, Director, 10% owner | Soldpre-planned (10b5-1) | 3,666 | $13.1K |
Who owns CVKD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Quang X. Pham13D, may seek influence with 1 related filers | 23.6% | January 29, 2025 |
Largest institutional holders
Insiders
1 insiders reported holding 98,589 shares in total, about $143K at the last price.
| Holder | Shares |
|---|---|
| Pham Quang XChairman and CEO, Director, 10% owner | 98,589 |
Questions about CVKD
What does Cadrenal Therapeutics, Inc. do?
Cadrenal Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CVKD. Its shares trade on NASDAQ under the ticker CVKD.
What is Cadrenal Therapeutics, Inc.'s net worth?
Cadrenal Therapeutics, Inc. has a market value (market cap) of $5.2M at the latest share price, and shareholders' equity of $4.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cadrenal Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11.5M.
When did Cadrenal Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 29, 2026.
When is Cadrenal Therapeutics, Inc.'s next earnings report?
Cadrenal Therapeutics, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Does Cadrenal Therapeutics, Inc. pay a dividend?
Yes. Cadrenal Therapeutics, Inc. declared dividends of $16.50 per share in fiscal 2025, a yield of 1,137.93% at the current price.
Similar companies
Compare CVKD with
Follow CVKD
Get an email when Cadrenal Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cadrenal Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.